Company intelligence / Profile preview

Nanjing Bold

Nanjing, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Nanjing Bold Pharmaceutical is a clinical-stage biopharmaceutical company based in China, focused on the discovery and development of innovative small molecule drugs for metabolic and inflammatory diseases. The company's lead program, BRP-001, is a potent URAT1 inhibitor currently in Phase 2 clinical trials for the treatment of hyperuricemia and gout. Beyond its metabolic portfolio, Nanjing Bold is advancing a pipeline of Toll-like receptor (TLR) modulators aimed at addressing unmet needs in chronic kidney disease and liver inflammation. The company leverages its internal R&D capabilities to transition candidates from early discovery through clinical proof-of-concept.

Therapeutic areas: ImmunologyNephrologyRheumatologyGastroenterologyMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Nanjing Bold.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nanjing Bold.

Explore the full profile